Human Resource and Employment Services

Insperity

Insperity released FY2026 Q1 earnings on April 30 Pre-Market (EST), actual revenue USD 1.895 B (forecast USD 1.893 B), actual EPS USD 0.88 (forecast USD 0.8612)

Insperity to Release FY2026 Q1 Earnings on April 30 Pre-Market EST, Forecast Revenue USD 1.893 B, EPS USD 0.8612

Insperity released FY2025 Q4 earnings on February 10 After-Market EST, actual revenue USD 1.668 B (forecast USD 1.678 B), actual EPS USD -0.8917 (forecast USD -0.7587)

Insperity released FY2025 Annual Earnings on February 10 After-Market (EST), actual revenue USD 6.812 B (forecast USD 6.822 B), actual EPS USD -0.19 (forecast USD -0.0793)

Insperity to Release FY2025 Q4 Earnings on February 10 After-Market EST, Forecast Revenue USD 1.678 B, EPS USD -0.7587

Martin's Stock Recommendations Yield 54.18% Success Rate

Insperity released FY2025 Q3 earnings on November 3 After-Market (EST), actual revenue USD 1.623 B (forecast USD 1.632 B), actual EPS USD -0.53 (forecast USD -0.09)

Insperity released FY2025 9 Months Earnings on November 3, After-Market EST: Actual Revenue USD 3.521 B, Actual EPS USD 1.2021

Insperity Inc revises healthcare insurance arrangement with UnitedHealthcare

Insperity to Release FY2025 Q3 Earnings on November 3 After-Market EST, Forecast Revenue USD 1.632 B, EPS USD -0.09

Insperity Director Tim Clifford Buys Company Stock

Insperity's EVP Increases Stock Holdings

Jefferies Financial Group Increases Stake in Insperity

Insperity released FY2025 Q2 earnings on August 1 Pre-Market EST, actual revenue USD 1.658 B (forecast USD 1.662 B), actual EPS USD -0.14 (forecast USD 0.0525)

Insperity released FY2025 Semi-Annual earnings on August 1 Pre-Market EST, actual revenue USD 3.521 B, actual EPS USD 1.2105

Insperity to Release FY2025 Q2 Earnings on August 1, Pre-Market EST; Forecast Revenue USD 1.662 B, EPS USD 0.0525

BNY Mellon Reduces Insperity Shares

Wealth Enhancement Advisors Significantly Boosts Insperity Holdings

UBS Asset Management Increases Stake in Insperity, Announces Quarterly Dividend

Insperity Inc. Holds Annual Shareholders' Meeting and Amends Incentive Plan

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

Vida Global

MetaVia

MicroAlgo

Tradr 2X Long XNDU Daily ETF

Insperity, Inc. (NYSE:NSP) has received a consensus rating of 'Reduce' from five research firms. Two analysts recommend selling, two suggest holding, and one advises buying. The average target price is $46.00. Recent insider transactions include CEO Paul J. Sarvadi purchasing 100,000 shares at $28.73 each. Institutional investors hold 93.44% of the stock. Insperity's shares opened at $31.59, with a 12-month low of $18.57 and a high of $71.96.

Market Beat

JPMorgan Chase

Charles Schwab

Goldman Sachs

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

SCHWAB(CHARLES)CORP 5.95% DEP SHS REP 1/40 NON CUM PERP PF D

SCHWAB(CHARLES)CORP 4.450% DEP SHS REP 1/40TH N-CUM PFD SERJ

GS Hldg R

Insperity, Inc. (NYSE:NSP) Given Consensus Rating of "Reduce" by Brokerages

Insperity, Inc. (NYSE:NSP) saw its stock price rise by 6.4% to $32.1680, despite a significant drop in trading volume. Analysts have mixed opinions, with price targets ranging from $33.00 to $56.00. The company reported earnings of $1.31 per share, exceeding estimates, and announced a quarterly dividend of $0.60 per share. Insider transactions showed significant stock purchases by executives. Institutional investors have also increased their stakes in the company recently.

Insperity (NYSE:NSP) Stock Price Up 6.4%  - What's Next?

On May 5, Insperity's CEO, Paul J. Sarvadi, purchased 100,000 shares of NSP for $2.87M at $28.73 each, seeing a 12.2% gain as NSP reached $32.25. Insperity's stock rose 9.2% that day. Previously, Sarvadi bought shares for $4.69M at $23.21 each. Meanwhile, Director G. Staley Cates bought 1,500 shares of Affiliated Managers Group for $458,745 at $305.83 each, with the stock down 0.7% on the same day.

nasdaq

Affiliated Managers

Nasdaq

Affiliated Managers Gp Pref Shares MGRE 6.75 Perp 03/30/64

Thursday 5/7 Insider Buying Report: NSP, AMG

Insperity (NYSE:NSP) reported Q1 2026 results exceeding management's expectations, with adjusted EPS at $1.31 and adjusted EBITDA at $103 million. Despite a 1% decline in average paid worksite employees, gross profit improved to $302 million, down 3% year-over-year. Operating expenses fell 1% to $240 million, including a $9 million restructuring charge. The company anticipates a shift in earnings seasonality due to a new UnitedHealthcare agreement. Insperity paid $23 million in dividends and repurchased shares worth $4 million, ending the quarter with $36 million in adjusted cash.

Unitedhealth

Insperity Q1 Earnings Call Highlights

Earnings Watch

Insperity | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 1.895 B

SMMT

TREE

RBLX

ATMU

RYAN

SNDX

ALHC

Summit Therapeutics(SMMT) fell 24.91%, with a trading turnover 290.9 Million USD, and a year-to-date fell 7.9%. LendingTree(TREE) fell 21.74%, with a trading turnover 59.4 Million USD, and a year-to-date fell 26.9%. Insperity(NSP) fell 19.79%, with a trading turnover 60.1 Million USD, and a year-to-date fell 24.2%.

Top Gainers&Losers

Summit Therapeutics

LendingTree

Roblox

Atmus Filtration Tech

Ryan Specialty

Syndax Pharma

Dolby Laboratories

Alignment Healthcare

Top 10 US Stock Losers (5.1)

William Blair analyst Andrew Nicholas maintains a Hold rating on Insperity (NSP) stock, citing a balance of margin progress against softer volume trends. Despite exceeding expectations on gross profit and adjusted EBITDA due to cost control, earnings per share were impacted by a higher tax rate. Management has reduced its outlook for worksite employee growth, anticipating a modest contraction. Truist Financial also reiterated a Hold rating with a $35.00 price target, indicating limited near-term upside for the shares.

Tip Ranks

Truist Financial

Insperity: Margin Progress Offsets Softer Volume as Outlook Cuts WSE Growth, Supporting Hold Rating

Insperity shares are trading lower after the company lowered its FY2026 adjusted EPS guidance.

benzinga_article

FNCL

J.P. Morgan analyst Andrew Polkowitz maintained a Sell rating on Insperity today and set a price target of $33.00.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks According to TipRanks, Polkowitz is ranked #3055 out of 12160 analysts. Insperity has an analyst consensus of Hold, with a price target consensus of $39.50.

Insperity(NSP.US)